In addition, this medication also suppresses gastric acid secretion and promotes satiety, resulting in appetite reduction
The STEP (Semaglutide Treatment Effect in People with Obesity) trials involved thousands of participants and demonstrated significant weight loss results while monitoring safety: Most participants experienced 15-20% weight loss over 68 weeks The safety profile was consistent with other GLP-1 receptor agonists Discontinuation rates due to adverse events were about 7% (compared to 3.1% with placebo) Trial participants maintained regular medical supervision throughout The STEP-1 trial, published in the New England Journal of Medicine, showed that semaglutide produced greater weight loss than any other FDA-approved anti-obesity medication to date, with a safety profile deemed acceptable by medical authorities
No allergic reactions like breakouts and other adverser reaction especially upset tummy, vomiting, headache, nausea, or whatsoever
Korobochka R, Gritsenko I, Gonen R, Ebstein RP, Ohel G
High growth rate of girls with precocious puberty exposed to estrogenic mycotoxins